HBV Treatment
AASLD 2011: Good Response to Entecavir Reduces Risk of Hepatitis B Liver Disease Progression
- Details
- Category: HBV Treatment
- Published on Tuesday, 22 November 2011 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients who achieve HBV DNA viral load suppression on entecavir (Baraclude) have a lower risk of liver failure, hepatocellular carcinoma, and death than non-responders, according to study findings presented this month at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
AASLD 2011: Long-term Tenofovir for HIV/HBV Coinfection
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 08 November 2011 00:00
- Written by Liz Highleyman
Tenofovir showed long-term antiviral activity against hepatitis B virus (HBV) lasting 5 to 8 years, with minimal evidence of kidney toxicity, and HBsAg levels declined steadily over time, according to 2 posters presented this week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
Gilead and GlobeImmune Will Collaborate on Hepatitis B Therapeutic Vaccine
- Details
- Category: HBV Treatment
- Published on Friday, 28 October 2011 00:00
- Written by Gilead & GlobeImmune
Gilead Sciences and GlobeImmune announced this week that they will collaborate on the development and commercialization of a hepatitis B virus (HBV) therapeutic vaccine using GlobeImmune's Tarmogen yeast vector technology. In contrast to widely used HBV preventive vaccines, therapeutic vaccines are designed to stimulate the body's immune response to the virus, and may be used in conjunction with oral antiviral drugs. 
AASLD 2011: Long-Term Tenofovir for Chronic Hepatitis B Reduces Liver Inflammation and Cirrhosis
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Gilead Sciences
Most chronic hepatitis B patients who maintain viral suppression on tenofovir (Viread) for 5 years experience improvement in liver histology, including regression of cirrhosis, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
Entecavir (Baraclude) Less Effective for Patients with Multidrug-Resistant Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 04 October 2011 00:00
- Written by Liz Highleyman
The nucleoside analog antiviral drug entecavir (Baraclude) was minimally effective against hepatitis B virus (HBV) that had already developed resistance to lamivudine (Epivir-HBV) and adefovir (Hepsera), researchers reported in the October 2011 Journal of Viral Hepatitis. Patient who achieved good early response, however, can do well if they stay on entecavir.
Web Design and Development by